Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 3, 2015, Pages 483-497

  Nagrial, Adnan M ^a,b   Chin, Venessa T ^a,b   Sjoquist, Katrin M ^c,d   Pajic, Marina ^a,b,e   Horvath, Lisa G ^a,b,f   Biankin, Andrew V ^a,b,g,h,i,j   Yip, Desmond ^k,l  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Chris O'Brien Lifehouse ^*  (Australia)

^g BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j GLASGOW ROYAL INFIRMARY   (United Kingdom)

^k CANBERRA HOSPITAL   (Australia)

^l The Australian National University   (Australia)

more..

Author keywords

Chemotherapy; Pancreatic cancer; Second line; Systematic review; Trials

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUFOSFAMIDE; IRINOTECAN; IRINOTECAN SUCROSOFATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PERIFOSINE; PHY 906; PX 12; RALTITREXED; RUBITECAN; SARACATINIB; SELUMETINIB; SUNITINIB; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BEST SUPPORTIVE CARE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); PANCREATIC NEOPLASMS; PROSPECTIVE STUDY; SALVAGE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84983135109     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.07.007     Document Type: Review

References (104)

1. Abbruzzese, J., Lenz, H., Hanna, W., Kindler, H., Scullin, D., Nemunaitis, J., et al. (Eds.), 2009. Open-label phase II study of S-1 as second-line therapy for patients with metastatic pancreatic cancer. Gastrointestinal Cancers Symposium.
2. Almhanna K., Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology 2008, 22(10):1176.
3. Androulakis N., Syrigos K., Polyzos A., Aravantinos G., Stathopoulos G.P., Ziras N., et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005, 23(1):9-12.
4. Astsaturov I.A., Meropol N.J., Alpaugh R.K., Burtness B.A., Cheng J.D., McLaughlin S., et al. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2011, 34(1):70-75.
5. Bai W.H.A.R., Pishvaian M.J., Slack R., Marshall J., Ley L., Dogra S., Hwang J.J. Pemetrexed as second-line treatment in patients with advanced pancreatic cancer progressing after gemcitabine. ASCO Gastrointestinal Cancers Symposium 2010, abs 276.
6. Blaszkowsky, L., Ryan, D., Earle, C., Kwak, E., Fuchs, C., Meyerhardt, J., et al. (Eds.), 2007. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. ASCO Meeting Abstracts.
7. Blaya M., Lopes G., Roman E., Ahn E., Macintyre J., Quesada J. Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer. ASCO Meeting Abstracts 2007, 25. abs s15029.
8. Blesa, J.G., Alberola-Candel, V., Marco, V.G. (Eds.), 2009. Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp). ASCO Meeting Abstracts.
9. Bodoky G., Timcheva C., Spigel D.R., La Stella P.J., Ciuleanu T.E., Pover G., et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. New Drugs 2012, 30(3):1216-1223. (Erratum appears in Invest. New Drugs 2012 June;30(3):1272-1273).
10. Boeck S., Weigang-Kohler K., Fuchs M., Kettner E., Quietzsch D., Trojan J., et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann. Oncol. 2007, 18(4):745-751.
11. Boeck S., Hoehler T., Seipelt G., Mahlberg R., Wein A., Hochhaus A., et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann. Oncol. 2008, 19(2):340-347.
12. Boeck S., Wilkowski R., Bruns C.J., Issels R.D., Schulz C., Moosmann N., et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2008, 73(3-4):221-227.
13. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002, 87(2):161-167.
14. Brell J.M., Matin K., Evans T., Volkin R.L., Kiefer G.J., Schlesselman J.J., et al. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009, 76(4):270-274.
15. Burris H.A., Rivkin S., Reynolds R., Harris J., Wax A., Gerstein H., et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005, 10(3):183-190.
16. Cantore M., Rabbi C., Fiorentini G., Oliani C., Zamagni D., Iacono C., et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004, 67(2):93-97.
17. Carvajal R.D., Tse A., Shah M.A., Lefkowitz R.A., Gonen M., Gilman-Rosen L., et al. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 2009, 9(4):404-409.
18. Cascinu S., Berardi R., Labianca R., Siena S., Falcone A., Aitini E., et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008, 9(1):39-44.
19. Cereda S., Reni M., Rognone A., Fugazza C., Ghidini M., Ceraulo D., et al. Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy 2011, 57(2):156-161.
20. Ciuleanu T.E., Pavlovsky A.V., Bodoky G., Garin A.M., Langmuir V.K., Kroll S., et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur. J. Cancer 2009, 45(9):1589-1596.
21. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Carteni G., Massidda B., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 Study. J. Clin. Oncol. 2010, 28(10):1645-1651.
22. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364(19):1817-1825.
23. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009, 27(33):5513-5518.
24. Custodio A., Puente J., Sastre J., Diaz-Rubio E. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat. Rev. 2009, 35(8):676-684.
25. Dahan L., Bonnetain F., Ychou M., Mitry E., Gasmi M., Raoul J.-L., et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010, 59(11):1527-1534.
26. Demols A., Peeters M., Polus M., Marechal R., Gay F., Monsaert E., et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br. J. Cancer 2006, 94(4):481-485.
27. El-Hadaad H.A., Wahba H.A. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. J. Gastrointest. Cancer 2013, 44(3):313-317.
28. Ettrich T.J., Von Wichert G., Gress T.M., Michl P., Geissler M., Hebart H.F., et al. DOCOX: a phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas. ASCO Meeting Abstracts 2013, 31(15 Suppl.). abs 4034.
29. Gebbia V., Maiello E., Giuliani F., Borsellino N., Caruso M., Di Maggio G., et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann. Oncol. 2007, 18(Suppl. 6):vi124-vi127.
30. Hedley, D., Moore, M., Hirte, H., Siu, L., Vincent, M., Jonker, D., et al. (Eds.), 2005. A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium. ASCO Meeting Abstracts.
31. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006, 24(24):3946-3952.
32. Heinemann V., Vehling-Kaiser U., Waldschmidt D., Kettner E., Marten A., Winkelmann C., et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013, 62(5):751-759.
33. Herrmann, T., Jaeger, D., Stremmel, W., Herrmann, C. (Eds.), 2007. Second-line chemotherapy in advanced pancreatic cancer: A retrospective, single-center analysis. ASCO Meeting Abstracts.
34. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schuller J., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 2007, 25(16):2212-2217.
35. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362(17):1605-1617.
36. Hosein P.J., de Lima Lopes G., Pastorini V.H., Gomez C., Macintyre J., Zayas G., et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am. J. Clin. Oncol. 2013, 36(2):151-156.
37. Ignatiadis M., Polyzos A., Stathopoulos G.P., Tselepatiotis E., Christophylakis C., Kalbakis K., et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006, 71(3-4):159-163.
38. Ioka, T., Katayama, K., Ishida, N., Takada, R., Yamai, T., Fukutake, N., et al. (Eds.), 2013, January 30. Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer. ASCO Meeting Abstracts.
39. Jacobs, A., Burris, H., Rivkin, S., Ritch, P., Eisenberg, P., Mettinger, K. (Eds.), 2004. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. ASCO Meeting Abstracts.
40. Javle M.M., Shroff R.T., Xiong H., Varadhachary G.A., Fogelman D., Reddy S.A., et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10(1):368.
41. Katopodis O., Polyzos A., Kentepozidis N., Giassas S., Rovithi M., Bozionelou V., et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother. Pharmacol. 2011, 67(2):361-368.
42. Kim Y.J., Bang S., Park J.Y., Park S.W., Chung J.B., Song S.Y. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother. Pharmacol. 2009, 63(3):529-533.
43. Kim H.J., Yun J., Kim K.H., Kim S.H., Lee T.H., Lee S.C., et al. Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncol. Lett. 2012, 3(6):1314-1318.
44. Kindler H.L., Aklilu M., Nattam S., Vokes E.E. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am. J. Clin. Oncol. 2008, 31(6):553-556.
45. Ko, A., Dito, E., Schillinger, B., Venook, A., Bergsland, E., Korn, W., et al. (Eds.), 2008. A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC). ASCO Meeting Abstracts.
46. Ko A.H., Dito E., Schillinger B., Venook A.P., Bergsland E.K., Tempero M.A. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008, 26(1):47-52.
47. Ko A., Tempero M., Shan Y., Su W., Lin Y., Dito E., et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br. J. Cancer 2013, 109(4):920-925.
48. Ko A.H., Tempero M.A., Bekaii-Saab T.B., Kuhn P., Courtin R., Ziyeh S., et al. Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: a multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib. ASCO Meeting Abstracts 2013, 31(15 Suppl.). abs 4014.
49. Kulke M.H., Blaszkowsky L.S., Ryan D.P., Clark J.W., Meyerhardt J.A., Zhu A.X., et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J. Clin. Oncol. 2007, 25(30):4787-4792.
50. Lohr J.M., Haas S.L., Bechstein W.O., Bodoky G., Cwiertka K., Fischbach W., et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann. Oncol. 2012, 23(5):1214-1222.
51. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005, 23(15):3509-3516.
52. Maisey N., Chau I., Cunningham D., Norman A., Seymour M., Hickish T., et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J. Clin. Oncol. 2002, 20(14):3130-3136.
53. Messersmith W.A., Nallapareddy S., Arcaroli J., Touban B., Tan A., Foster N., et al. A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer. Gastrointestinal Cancers Symposium 2010, abstr e14515.
54. Milella M., Gelibter A., Di Cosimo S., Bria E., Ruggeri E.M., Carlini P., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101(1):133-138.
55. Mitry E., Ducreux M., Ould-Kaci M., Boige V., Seitz J.-F., Bugat R., et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma: results of a phase II trial. Gastroenterol. Clin. Biol. 2006, 30(3):357-363.
56. Mizuno, N., Yamao, K., Komatsu, Y., Munakata, M., Ishiguro, A., Yamaguchi, T., et al. (Eds.), 2013, January 30. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. ASCO Meeting Abstracts.
57. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151(4):264-269. W64.
58. Morizane C., Okusaka T., Furuse J., Ishii H., Ueno H., Ikeda M., et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2009, 63(2):313-319.
59. Nakai Y., Isayama H., Sasaki T., Sasahira N., Tsujino T., Toda N., et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br. J. Cancer 2012, 106(12):1934-1939. PMCID: 3388559.
60. Nakamori S., Tsujie M., Miyamoto A., Kurokawa Y., Yasui M., Ikenaga M. Impact of the combination of S-1 administration prior to gemcitabine as a second-line therapy for unresectable/recurrent pancreatic cancer. ASCO Gastrointestinal Cancers Symposium 2010, abs 241.
61. Ng, M., Norman, A., Cunningham, D., Waters, J., Oates, J., Ross, P. (Eds.), 2004. Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy. ASCO Meeting Abstracts.
62. Novarino A., Satolli M.A., Chiappino I., Giacobino A., Bellone G., Rahimi F., et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am. J. Clin. Oncol. 2009, 32(1):44-48.
63. Oettle H., Arnold D., Esser M., Huhn D., Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000, 11(8):635-638.
64. Oettle H., Richards D., Ramanathan R., Van Laethem J.-L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 2005, 16(10):1639-1645.
65. Oh S.Y., Kim H.J., Kim T.H., Lee G.W., Kim H.G., Jeong C.Y., et al. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer. Invest. New Drugs 2010, 28(3):343-349.
66. O'Reilly E.M., Niedzwiecki D., Hall M., Hollis D., Bekaii-Saab T., Pluard T., et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010, 15(12):1310-1319.
67. Ozaka M., Matsumura Y., Ishii H., Omuro Y., Itoi T., Mouri H., et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother. Pharmacol. 2012, 69(5):1197-1204.
68. Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Gorner M., et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. ASCO Meeting Abstracts 2008, 26(15 Suppl.). abs 4508.
69. Pelzer U., Stieler J., Roll L., Hilbig A., Dorken B., Riess H., et al. Second-line therapy in refractory pancreatic cancer: results of a phase II study. Onkologie 2009, 32(3):99-102.
70. Pelzer U., Schwaner I., Stieler J., Adler M., Seraphin J., Dorken B., et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer 2011, 47(11):1676-1681.
71. Petrelli F., Borgonovo K., Ghilardi M., Cabiddu M., Barni S. What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. Rev. Recent Clin. Trials 2010, 5(1):43-56.
72. Poplin E., Wasan H., Rolfe L., Raponi M., Ikdahl T., Bondarenko I., et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J. Clin. Oncol. 2013, 31(35):4453-4461.
73. Rahma O.E., Duffy A., Liewehr D.J., Steinberg S.M., Greten T.F. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann. Oncol. 2013, 24(8):1972-1979.
74. Ramanathan R.K., Abbruzzese J., Dragovich T., Kirkpatrick L., Guillen J.M., Baker A.F., et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother. Pharmacol. 2011, 67(3):503-509.
75. Rebonato A., Mambrini A., Auci A., Puccianti F., Petruzzi P., Sanguinetti F.R., et al. Intra-arterial and systemic chemotherapy as second line treatment for advanced pancreatic carcinoma: a phase II study. Cardiovasc. Interv. Radiol. 2011, 34:607.
76. Reni M., Cordio S., Milandri C., Passoni P., Bonetto E., Oliani C., et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005, 6(6):369-376.
77. Reni M., Pasetto L., Aprile G., Cordio S., Bonetto E., Dell'Oro S., et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br. J. Cancer 2006, 94(6):785-791. PMCID: 2361378.
78. Renouf D.J., Tang P.A., Major P., Krzyzanowska M.K., Dhesy-Thind B., Goffin J.R., et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest. New Drugs 2012, 30(3):1203-1207.
79. Rocha Lima C.M., Green M.R., Rotche R., Miller W.H., Jeffrey G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 2004, 22(18):3776-3783.
80. Rothenberg M.L., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris H.A., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996, 7(4):347-353.
81. Rothenberg M., Benedetti J., Macdonald J., Seay T., Neubauer M., George C., et al. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group Study. Ann. Oncol. 2002, 13(10):1576-1582.
82. Saif M., Li J., Lamb L., Kaley K., Bussom S., Carbone R., et al. Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines. ASCO Meeting Abstracts 2010, 28(15 Suppl.). abs e14540.
83. Scheithauer W., Scholl B., Ulrich-Pur H., Schmid K., Raderer M., Haider K., et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann. Oncol. 2003, 14(1):97-104.
84. Seufferlein T., Bachet J.B., Van Cutsem E., Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23(Suppl. 7):vii33-vii40.
85. Sharma J.J., Razvillas B., Stephens C.D., Hilsenbeck S.G., Sharma A., Rothenberg M.L. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest. New Drugs 1997, 15(4):361-364.
86. Shi S.-B., Wang M., Niu Z.-X., Tang X.-Y., Liu Q.-Y. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Pancreatology 2012, 12(6):475-479.
87. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64(1):9-29.
88. Stathopoulos G.P., Syrigos K., Aravantinos G., Polyzos A., Papakotoulas P., Fountzilas G., et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br. J. Cancer 2006, 95(5):587-592.
89. Stathopoulos G.P., Boulikas T., Vougiouka M., Rigatos S.K., Stathopoulos J.G. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep. 2006, 15(5):1201-1204.
90. Sudo K., Yamaguchi T., Nakamura K., Denda T., Hara T., Ishihara T., et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2011, 67(2):249-254.
91. Tang, P., Gill, S., Au, H., Chen, E., Hedley, D., Leroux, M., et al. (Eds.), 2009. Phase II trial of erlotinib in advanced pancreatic cancer (PC). ASCO Meeting Abstracts.
92. Tempero M.A., Arnoletti J.P., Behrman S.W., Ben-Josef E., Benson A.B., Casper E.S., et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J. Natl. Compr. Cancer Netw. 2012, 10(6):703-713.
93. Togawa A., Yoshitomi H., Ito H., Kimura F., Shimizu H., Ohtsuka M., et al. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int. J. Clin. Oncol. 2007, 12(4):268-273.
94. Tsavaris N., Kosmas C., Skopelitis H., Gouveris P., Kopterides P., Loukeris D., et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest. New Drugs 2005, 23(4):369-375.
95. Ueno H., Ioka T., Ikeda M., Ohkawa S., Yanagimoto H., Boku N., et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST Study. J. Clin. Oncol. 2013, 31(13):1640-1648.
96. Ulrich-Pur H., Raderer M., Verena Kornek G., Schull B., Schmid K., Haider K., et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br. J. Cancer 2003, 88(8):1180-1184.
97. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27(13):2231-2237.
98. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369(18):1691-1703.
99. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27(2):193-198.
100. Wu, Z., Marshall, J., Hwang, J.J., Pishvaian, M.J., Wellstein, A., Weiner L.M., et al. (Eds.), 2012. A phase II study of lapatinib and capecitabine in second-line treatment of metastatic pancreatic cancer. ASCO Meeting Abstracts.
101. Xiong H.Q., Varadhachary G.R., Blais J.C., Hess K.R., Abbruzzese J.L., Wolff R.A. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008, 113(8):2046-2052.
102. Yi S.Y., Park Y.S., Kim H.S., Jun H.J., Kim K.H., Chang M.H., et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2009, 63(6):1141-1145.
103. Yoo C., Hwang J.Y., Kim J.E., Kim T.W., Lee J.S., Park D.H., et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br. J. Cancer 2009, 101(10):1658-1663.
104. Zaniboni A., Aitini E., Barni S., Ferrari D., Cascinu S., Catalano V., et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother. Pharmacol. 2012, 69(6):1641-1645.